Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Cyclacel Pharmaceuticals announced participation in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cyclacel Pharmaceuticals announced participation in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022. The event will take place at 9:30 AM ET in Track 2, St Germain III, New York. A fireside chat presentation format will be used. Cyclacel is focused on developing innovative cancer treatments, particularly through its lead candidates, fadraciclib and CYC140, targeting solid tumors and hematological malignancies. For further details, visit cyclacel.com.
Details
News Market Reaction – CYCC
The recorded move for CYCC in the trading session of this news was +6.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann’s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.
| Event: | Ladenburg Thalmann 2022 Healthcare Conference |
| Date: | Thursday, September 29, 2022 |
| Time/location: | 9:30am ET, Track 2, St Germain III |
| Format: | Fireside Chat Presentation |
| Webcast: | Link |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Contacts
| Company: | Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
| Investor Relations: | Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, ikoffler@lifesciadvisors.com |
© Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.